Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ecopetrol SA (EC) vs Johnson & Johnson (JNJ) Price & Performance

Ecopetrol SATrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Ecopetrol SA vs Johnson & Johnson — how do they compare? Ecopetrol SA trades at $15.99 (market cap $30.44B), while Johnson & Johnson trades at $250.58 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 19.5× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (4.06%). Which is the better fit depends on your goals.

ECJNJ
Market Cap
$30.44B$594.63B
Sector
EnergyHealth
52-Week High
$16.58$267.24
52-Week Low
$8.29$162.98
Enterprise Value
$58.23B$627.57B
Dividend Yield
4.06%2.17%
Volume
6,156,228

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ecopetrol SA

Ecopetrol (EC) trades at $16.16, up 1.76% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company maintains solid profitability with an 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6T in 2022 to $119.7T in 2025. Recent developments include a finalized labor agreement with the USO union and S&P affirming its BB- credit rating with a stable outlook on June 17, 2026.

The stock presents a mixed outlook: valuation appears reasonable with a P/E of 11.39, but earnings misses and declining revenue pose risks. Analyst consensus is cautious with a $14.63 price target below current levels. Key opportunities include stable cash flow and dividend payments, while risks involve oil price volatility and execution challenges in a competitive energy sector.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $253.85, down 1.52% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 earnings of $2.70 per share, beating estimates, and raised its full-year 2026 outlook. Revenue grew 6.6% annually in Q2 2026, driven by strength in Innovative Medicine and new product launches, though MedTech sales slightly missed expectations.

JNJ offers a compelling investment case with a 64-year dividend king status, robust profitability, and raised guidance, but faces risks from patent expirations and competitive pressures. Analyst consensus is bullish with a $281 price target, suggesting ~11% upside, supported by strong institutional confidence and innovation in AI and robotics targeting $100 billion revenue.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ecopetrol SA

Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.

Read more on EC

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ